Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
FDA Approval of Mitapivat: Redefining Thalassemia Management
RishiRaj Sinha/LinkedIn
Jan 17, 2026, 04:53

FDA Approval of Mitapivat: Redefining Thalassemia Management

Dr RishiRaj Sinha, Member, Public Health Partnerships Subgroup Working Party at International Society of Blood Transfusion (ISBT), posted on LinkedIn:

“A Historic Breakthrough and most Recent Advance in Thalassemia Care.

For decades, blood transfusions and chelation were the backbone of thalassemia management.
Today, that narrative changes.

The FDA has approved mitapivat, the first-ever oral therapy for adults with α- and β-thalassemia, applicable to both transfusion-dependent and non-transfusion-dependent patients.

Mechanism of Action (Why this drug is different).

Mitapivat is a pyruvate kinase (PKR) activator.

  • It enhances red cell glycolysis.
  • Increases ATP production within erythrocytes.
  • Improves red cell survival and function.
  • Reduces ineffective erythropoiesis and hemolysis.

Instead of replacing red cells (like transfusions), mitapivat optimizes the energy metabolism of existing RBCs, a true disease-modifying approach.

Safety and Monitoring of Mitapivat:
Mitapivat carries a boxed warning for hepatocellular injury and is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.

This is not just another approval.
This is a paradigm shift in anemia management.

Why this approval is game-changing:

  • First oral disease-modifying option in thalassemia,
  • Demonstrated hemoglobin improvement in pivotal trials,
  • Potential reduction in transfusion burden,
  • Improved fatigue, function, and quality of life ,
  • A long-awaited win for patients and clinicians alike.

Backed by the ENERGIZE & ENERGIZE-T trials, this approval marks the arrival of precision-targeted metabolic therapy in inherited hemoglobinopathies.

For the global thalassemia community, this represents hope beyond transfusions. For clinicians, it signals the dawn of a new therapeutic era.

Progress is real. Science delivered. Patients benefit.”

For more information.

Find more posts featuring Dr RishiRaj Sinha on Hemostasis Today.

 

Dr RishiRaj Sinha Health Hematology Hemostasis Today Medical News Medicine Mitapivat Thalassemia thrombosis
NewsFeed